Browsing Tag
anal cancer
2 posts
How the FDA meeting could redefine pelareorep’s registrational path in anal cancer
Could Oncolytics Biotech redefine pelareorep’s approval path in anal cancer? Read what the FDA meeting means for commercialization and investor sentiment.
Is pelareorep gaining traction? Oncolytics Biotech’s updated GOBLET data draws investor focus to third-line anal cancer
Find out why Oncolytics Biotech’s updated GOBLET cohort 4 data is drawing investor attention to pelareorep’s role in third-line anal cancer.